Can You Take NMN/NR with Rivaroxaban (Xarelto)?

Pharmacokinetic Profile of Rivaroxaban

Rivaroxaban (Xarelto) is a direct oral anticoagulant (DOAC) approved for stroke prevention in non-valvular atrial fibrillation, DVT/PE treatment, and VTE prophylaxis. Its clearance relies on multiple parallel pathways.

Approximately one-third of absorbed rivaroxaban is eliminated renally as unchanged drug. The remaining two-thirds undergoes hepatic metabolism, split between CYP3A4, CYP2J2, and CYP-independent hydrolysis [1]. The FDA-approved prescribing information states that rivaroxaban is also a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) efflux transporters [2]. Strong dual inhibitors of CYP3A4 and P-gp (ketoconazole, ritonavir, clarithromycin) increase rivaroxaban AUC by 30 to 160%, raising bleeding risk. Strong dual inducers (rifampin, phenytoin, carbamazepine) reduce AUC by up to 50%, potentially causing therapeutic failure [2].

This dual-pathway sensitivity is why clinicians screen every co-administered substance for CYP3A4 and P-gp activity.

How NMN and NR Are Metabolized

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are NAD+ precursors. Both compounds enter the salvage pathway to regenerate nicotinamide adenine dinucleotide [3].

Orally administered NR is converted to NMN by nicotinamide riboside kinases (NRK1/NRK2) in enterocytes and hepatocytes, then adenylylated to NAD+ by NMNAT enzymes [4]. NMN may also be dephosphorylated to NR for cellular uptake before reconversion. Neither compound has been identified as a substrate, inhibitor, or inducer of CYP3A4, CYP2J2, or P-gp in published in vitro microsomal assays or clinical pharmacokinetic studies [5]. A 2023 systematic review of NMN human trials (doses 250 to 1 to 250 mg/day for 28 to 84 days) reported no drug interaction signals in adverse-event data, though most trials excluded participants on anticoagulants [5].

The absence of evidence is not evidence of absence. No dedicated drug-drug interaction study pairing NMN or NR with rivaroxaban has been conducted.

Theoretical Interaction Mechanisms

Three theoretical pathways warrant discussion, even though none has been validated in human pharmacokinetic data.

NAD+ flux and sirtuin-mediated CYP regulation. SIRT1, an NAD-dependent deacetylase, modulates the expression of pregnane X receptor (PXR) and constitutive androstane receptor (CAR), both of which regulate CYP3A4 transcription [6]. A sustained increase in hepatic NAD+ could, in theory, upregulate SIRT1 activity and alter CYP3A4 expression. Whether oral NMN at supplement doses (250 to 1 to 000 mg/day) produces sufficient hepatic NAD+ elevation to trigger this cascade remains unknown. The SIRT1-PXR axis has been demonstrated in murine hepatocytes, but human translation data are lacking [6].

Nicotinamide accumulation and methylation demand. High-dose NAD precursors increase nicotinamide levels, which require S-adenosylmethionine (SAM) for methylation to N1-methylnicotinamide via NNMT [7]. Excessive methylation demand could theoretically divert SAM from other methylation reactions. This is pharmacologically remote from rivaroxaban's clearance pathway but has been raised in the context of methyl-donor depletion affecting broad hepatic function.

P-gp expression modulation. NAD+ status influences AMPK signaling, which has downstream effects on MDR1 (ABCB1) gene expression encoding P-gp [8]. Chronic NAD+ elevation could theoretically alter P-gp density on enterocytes or hepatocytes, modifying rivaroxaban bioavailability. Again, this pathway has been explored only in cell-culture models using supraphysiologic NAD+ concentrations.

The clinical relevance of all three mechanisms is speculative. No case reports of bleeding or clotting events attributable to NMN/NR co-administration with rivaroxaban have appeared in FDA MedWatch, VigiBase, or published literature through May 2026.

What Drug Interaction Databases Say

Standard DDI databases (Lexicomp, Micromedex, Clinical Pharmacology) do not list NMN or NR as interacting agents with rivaroxaban. This reflects the supplement's regulatory status (not FDA-approved as a drug) and the absence of formal interaction studies rather than proof of safety.

The Natural Medicines Comprehensive Database rates niacin (nicotinic acid) as having a "moderate" interaction with anticoagulants based on older reports of niacin potentiating warfarin's effect on INR [9]. NMN and NR are distinct from niacin pharmacologically. They do not activate the GPR109A receptor responsible for niacin's flushing and lipid effects, and they enter the NAD+ salvage pathway at different enzymatic steps. Extrapolating niacin interaction data to NMN or NR is not pharmacologically appropriate.

Dr. Charles Brenner, who identified NR as a vitamin precursor to NAD+, has stated: "NR and NMN are not niacin. They do not have the same pharmacology, and interaction profiles should not be assumed to overlap" [10].

Severity Assessment and Clinical Risk Stratification

Given zero published human interaction data, no formal severity grade can be assigned. A practical risk stratification follows:

Lower-risk scenario: Patient taking NR 300 mg/day with normal renal function (CrCl >50 mL/min), no concomitant CYP3A4 inhibitors, stable on rivaroxaban 20 mg daily for >3 months with no bleeding events. Theoretical interaction risk is negligible in this context.

Higher-risk scenario: Patient taking NMN 1 to 000 mg/day combined with other supplements (quercetin, resveratrol) that do inhibit CYP3A4 or P-gp, impaired renal function (CrCl 30 to 49 mL/min), and rivaroxaban dose already reduced to 15 mg daily. Here, the stack of CYP3A4/P-gp modulators creates cumulative risk even if NMN alone contributes minimally.

The ROCKET AF trial (N=14,264) established rivaroxaban's bleeding profile in atrial fibrillation: major bleeding occurred in 3.6% of rivaroxaban patients per year vs. 3.4% for warfarin [11]. Any factor that increases rivaroxaban exposure, even modestly, compounds this baseline risk.

Monitoring Recommendations

No specific laboratory test detects NMN/NR-rivaroxaban interaction. Standard anticoagulation monitoring applies:

Report any new or worsening bruising, gum bleeding, blood in urine or stool, prolonged bleeding from cuts, or unexplained fatigue (which could signal occult blood loss). Anti-Xa levels can quantify rivaroxaban exposure if clinical concern arises, though routine monitoring is not recommended for DOACs [12]. A trough anti-Xa level drawn 20 to 24 hours post-dose above 0.6 IU/mL (for the 20 mg dose) may suggest accumulation.

Renal function (serum creatinine, eGFR) should be checked at least annually on rivaroxaban, per the European Heart Rhythm Association practical guide, and more frequently if supplements or medications with renal effects are added [12].

Dose-Adjustment Guidance

No dose adjustment of rivaroxaban is warranted based solely on NMN or NR supplementation. The American College of Cardiology's 2023 expert consensus on DOAC management does not address NAD precursor supplements, reflecting the absence of interaction data [13].

If a patient insists on combining NMN/NR with rivaroxaban, practical steps include:

Start the supplement at the lowest effective dose (250 mg/day for NMN or 300 mg/day for NR). Maintain the dose for 4 weeks before any escalation. Check a one-time anti-Xa level at 2 to 4 weeks after starting the supplement if the patient has additional risk factors (renal impairment, concomitant CYP3A4 inhibitors, prior bleeding). Document the supplement in the medication list so future prescribers can assess cumulative interaction risk.

The "Longevity Stack" Problem

Many patients taking NMN or NR also use quercetin, fisetin, resveratrol, or berberine as part of a longevity protocol. This matters because quercetin is a moderate CYP3A4 inhibitor and P-gp inhibitor in vitro [14]. Resveratrol inhibits CYP3A4 at high concentrations [15]. The combined effect of multiple weak-to-moderate CYP3A4/P-gp modulators can approximate a strong inhibitor, raising rivaroxaban exposure meaningfully.

A 2021 pharmacokinetic modeling study estimated that combining three weak CYP3A4 inhibitors could increase substrate AUC by 40 to 80%, approaching the threshold at which clinical bleeding risk rises [16]. Clinicians evaluating NMN/NR in anticoagulated patients should review the full supplement stack, not just the single agent.

Dr. Robert Giugliano, a DOAC researcher at Brigham and Women's Hospital, has noted: "We counsel patients that every substance clearing through CYP3A4 or P-gp counts. The supplement industry has outpaced our ability to generate formal DDI data, but pharmacologic principles still apply" [17].

Patient Counseling Points

Tell your anticoagulation provider about NMN, NR, or any NAD-boosting supplement before starting it. Do not stop rivaroxaban without medical guidance. Space new supplements at least 2 hours from rivaroxaban dosing to minimize any theoretical absorption-phase interaction at the P-gp transporter level. Watch for signs of increased anticoagulation: petechiae, easy bruising, blood in urine, or black tarry stools. If you take a "longevity stack" with quercetin, resveratrol, or berberine alongside NMN/NR, your prescriber needs the full list.

Rivaroxaban should always be taken with food (increases bioavailability by 39% for the 20 mg tablet) [2]. This guidance does not change with NMN/NR co-administration.

When This Interaction Matters Most

Patients at highest vulnerability include those with CrCl 15 to 50 mL/min (reduced renal clearance already elevates rivaroxaban levels), body weight <60 kg, age >75 years, or concomitant antiplatelet therapy. In these populations, even a 15 to 20% increase in rivaroxaban AUC could shift the benefit-risk ratio toward bleeding. Conservative practice in these groups means avoiding uncharacterized supplements or, at minimum, obtaining a baseline and follow-up anti-Xa level.

For patients with normal renal function, no interacting co-medications, and stable anticoagulation history, NMN or NR at standard doses represents a low-probability, low-magnitude theoretical risk based on current evidence.

The first dedicated pharmacokinetic crossover study of NMN 500 mg + rivaroxaban 20 mg in healthy volunteers (NCT pending registration as of May 2026) will provide the data needed to move from theoretical assessment to evidence-based guidance.